- Home
- ACLX vs PTGX Comparison
ACLX vs PTGX Comparison
Compare ACLX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- PTGX
- Stock Information
- Founded
- ACLX 2015
- PTGX 2006
- Country
- ACLX United States
- PTGX United States
- Employees
- ACLX N/A
- PTGX N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- ACLX Health Care
- PTGX Health Care
- Exchange
- ACLX Nasdaq
- PTGX Nasdaq
- Market Cap
- ACLX 3.3B
- PTGX 2.8B
- IPO Year
- ACLX 2022
- PTGX 2016
- Fundamental
- Price
- ACLX $57.55
- PTGX $42.97
- Analyst Decision
- ACLX Strong Buy
- PTGX Strong Buy
- Analyst Count
- ACLX 14
- PTGX 8
- Target Price
- ACLX $109.33
- PTGX $66.50
- AVG Volume (30 Days)
- ACLX 715.8K
- PTGX 990.2K
- Earning Date
- ACLX 05-08-2025
- PTGX 05-06-2025
- Dividend Yield
- ACLX N/A
- PTGX N/A
- EPS Growth
- ACLX N/A
- PTGX N/A
- EPS
- ACLX N/A
- PTGX 0.86
- Revenue
- ACLX $76,809,000.00
- PTGX $207,801,000.00
- Revenue This Year
- ACLX N/A
- PTGX N/A
- Revenue Next Year
- ACLX $96.17
- PTGX $7.13
- P/E Ratio
- ACLX N/A
- PTGX $50.68
- Revenue Growth
- ACLX N/A
- PTGX N/A
- 52 Week Low
- ACLX $47.88
- PTGX $24.22
- 52 Week High
- ACLX $107.37
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- ACLX 42.15
- PTGX 43.08
- Support Level
- ACLX $47.86
- PTGX $41.29
- Resistance Level
- ACLX $67.36
- PTGX $46.12
- Average True Range (ATR)
- ACLX 4.20
- PTGX 1.83
- MACD
- ACLX -0.70
- PTGX -0.19
- Stochastic Oscillator
- ACLX 49.69
- PTGX 27.81
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.